Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery
- Conditions
- Breast Cancer
- Registration Number
- NCT00039546
- Lead Sponsor
- Cancer Research Campaign Clinical Trials Centre
- Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective in treating women after surgery for breast cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel, epirubicin, and cyclophosphamide with or without gemcitabine in treating women who have undergone surgery for breast cancer.
- Detailed Description
OBJECTIVES:
* Compare the 5-year and 10-year disease-free survival and overall survival of women with completely resected early stage breast cancer treated with adjuvant paclitaxel, epirubicin, and cyclophosphamide with or without gemcitabine.
* Compare the toxicity, dose-intensity, and tolerability of these regimens in these patients.
* Compare the serious adverse events in patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to nodal status (negative vs 1-3 vs 4 or more), age (50 and under vs over 50), estrogen receptor status (negative vs weakly positive vs positive), concurrent radiotherapy (no vs yes), HER2 status (3+ overexpression vs other vs not measured), and country. Patients are randomized to 1 of 2 treatment arms.
* Arm I: Patients receive epirubicin IV, cyclophosphamide IV, and paclitaxel IV over 3 hours on day 1. Patients also receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
* Arm II: Patients receive epirubicin, cyclophosphamide, and paclitaxel as in arm I.
Patients are followed every 3 months for 6 months, every 6 months for 3 years, and then annually for 6 years.
PROJECTED ACCRUAL: A total of 3,000 patients (1,500 per treatment arm) will be accrued for this study within 3-4 years.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (46)
Queen Elizabeth Hospital at University of Birmingham
🇬🇧Birmingham, England, United Kingdom
Cancer Research UK Clinical Trials Unit - Birmingham
🇬🇧Birmingham, England, United Kingdom
City Hospital - Birmingham
🇬🇧Birmingham, England, United Kingdom
Birmingham Heartlands and Solihull NHS Trust -Teaching
🇬🇧Birmingham, England, United Kingdom
Queen's Hospital, Burton
🇬🇧Burton-upon-Trent, England, United Kingdom
Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust
🇬🇧Cambridge, England, United Kingdom
Broomfield Hospital
🇬🇧Chelmsford, Essex, England, United Kingdom
Essex County Hospital
🇬🇧Colchester, England, United Kingdom
Walsgrave Hospital
🇬🇧Coventry, England, United Kingdom
Dorset County Hospital
🇬🇧Dorchester, England, United Kingdom
Scroll for more (36 remaining)Queen Elizabeth Hospital at University of Birmingham🇬🇧Birmingham, England, United Kingdom